540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy
Year: 2020
Type: article
Source: Annals of Oncology
Institutions: Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, University of Colorado Anschutz, University of Minnesota, Yonsei Cancer Hospital, Samsung Medical Center, Taipei Veterans General Hospital, Massachusetts General Hospital, National Cancer Center Hospital East, National Cancer Center Hospital, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, Centre Léon Bérard, National Cancer Centre Singapore, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, F. Hoffmann-La Roche AG, Genentech, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, International Association for the Study of Lung Cancer, Teva Pharmaceutical Industries, Ariad Pharmaceuticals, Celgene, F. Hoffmann-La Roche, Helsinn, Taiho Pharmaceutical, Exelixis, Les Laboratories Pierre Fabre, Mylan, BeiGene, Sysmex Corporation, Celltrion, Yuhan, Eisai, Kyowa Hakko Kirin, Astellas Pharma, Basilea Pharmaceutica, Servier, PharmaMar, Ono Pharmaceutical, Ipsen, National Institutes of Health, Genentech, Chugai Pharmaceutical, Ignyta, Loxo Oncology, Foundation Medicine, Daiichi Sankyo Europe
OpenAlex ID: W3088166637